Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

This study is testing a drug called lisaftoclax (APG-2575) alone or in combination with other cancer drugs (including acalabrutinib, obinutuzumab, or venetoclax) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to treatment. **You may be eligible if...** - You are 18 or older - You have CLL or SLL confirmed by diagnosis that has relapsed or is not responding to at least one prior therapy - Your disease shows signs of progression (rising white blood cell counts, enlarging lymph nodes or spleen) - Your general health is adequate (ECOG 0–2) - Treatment-naive patients may also be eligible for the lisaftoclax plus acalabrutinib combination **You may NOT be eligible if...** - You have not had at least one prior line of therapy for CLL/SLL (except for certain combination cohorts) - Your organ function is too impaired for treatment - You do not have documented disease progression Talk to your doctor to see if this trial is right for you.